Top

BMC Cancer

Published in:

Open Access 01-12-2024 | NSCLC | Research

Stereotactic ablative brachytherapy versus percutaneous microwave ablation for early-stage non-small cell lung cancer: a multicenter retrospective study

Authors: Chuanwang Wu, Binglong Cao, Guanghui He, Yuliang Li, Wujie Wang

Published in: BMC Cancer | Issue 1/2024

Abstract

Background

To analyze the efficacy of stereotactic ablative brachytherapy (SABT) and percutaneous microwave ablation (MWA) for the treatment of early-stage non-small cell lung cancer (NSCLC).

Methods

Patients with early-stage (T1-T2aN0M0) NSCLC who underwent CT-guided SABT or MWA between October 2014 and March 2017 at four medical centers were retrospectively analyzed. Survival, treatment response, and procedure-related complications were assessed.

Results

A total of 83 patients were included in this study. The median follow-up time was 55.2 months (range 7.2–76.8 months). The 1-, 3-, and 5-year overall survival (OS) rates were 96.4%, 82.3%, and 68.4% for the SABT group (n = 28), and 96.4%, 79.7%, and 63.2% for MWA group (n = 55), respectively. The 1-, 3-, and 5-year disease-free survival (DFS) rates were 92.9%, 74.6%, and 54.1% for SABT, and 92.7%, 70.5%, and 50.5% for MWA, respectively. There were no significant differences between SABT and MWA in terms of OS (p = 0.631) or DFS (p = 0.836). The recurrence rate was also similar between the two groups (p = 0.809). No procedure-related deaths occurred. Pneumothorax was the most common adverse event in the two groups, with no significant difference. No radiation pneumonia was found in the SABT group.

Conclusions

SABT provided similar efficacy to MWA for the treatment of stage I NSCLC. SABT may be a treatment option for unresectable early-stage NSCLC. However, future prospective randomized studies are required to verify these results.

Siegel RL, Miller KD, Fuchs HE, Jemal A, Cancer Statistics. 2022. CA: a cancer journal for clinicians 2022; 72(1):7–33. Epub 2022/01/13. https://doi.org/10.3322/caac.21708.

Meza R, Meernik C, Jeon J, Cote ML. Lung Cancer Incidence trends by gender, race and histology in the United States, 1973–2010. PLoS ONE. 2015;10(3):e0121323. https://doi.org/10.1371/journal.pone.0121323. Epub 2015/03/31.CrossRefPubMedPubMedCentral

Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, et al. Reduced lung-Cancer mortality with low-dose computed Tomographic Screening. N Engl J Med. 2011;365(5):395–409. https://doi.org/10.1056/NEJMoa1102873. Epub 2011/07/01.CrossRefPubMed

Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. Early and locally Advanced Non-small-cell Lung Cancer (NSCLC): Esmo Clinical Practice guidelines for diagnosis, treatment and Follow-Up. Annals Oncology: Official J Eur Soc Med Oncol. 2017;28(suppl4):iv1–iv21. https://doi.org/10.1093/annonc/mdx222. Epub 2017/09/09.CrossRef

Rami-Porta R, Tsuboi M. Sublobar Resection for Lung Cancer. Eur Respir J. 2009;33(2):426–35. https://doi.org/10.1183/09031936.00099808. Epub 2009/02/03.CrossRefPubMed

Dupuy DE, Fernando HC, Hillman S, Ng T, Tan AD, Sharma A, et al. Radiofrequency ablation of stage Ia Non-small Cell Lung Cancer in medically inoperable patients: results from the American College of Surgeons Oncology Group Z4033 (Alliance) Trial. Cancer. 2015;121(19):3491–8. https://doi.org/10.1002/cncr.29507. Epub 2015/06/23.CrossRefPubMed

Palussière J, Catena V, Lagarde P, Cousin S, Cabart M, Buy X, et al. Primary tumors of the lung: should we consider thermal ablation as a valid therapeutic option? Int J Hyperth. 2019;36(2):46–52. https://doi.org/10.1080/02656736.2019.1647351. Epub 2019/09/21.CrossRef

Tafti BA, Genshaft S, Suh R, Abtin F. Lung ablation: indications and techniques. Semin Interv Radiol. 2019;36(3):163–75. https://doi.org/10.1055/s-0039-1693981. Epub 2019/08/23.CrossRef

Videtic GM, Paulus R, Singh AK, Chang JY, Parker W, Olivier KR, et al. Long-term follow-up on Nrg Oncology Rtog 0915 (Ncctg N0927): a randomized phase 2 study comparing 2 stereotactic body Radiation Therapy schedules for medically inoperable patients with stage I Peripheral Non-small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2019;103(5):1077–84. https://doi.org/10.1016/j.ijrobp.2018.11.051. Epub 2018/12/05.CrossRefPubMed

10.

Dupuy DE. Image-guided thermal ablation of lung malignancies. Radiology. 2011;260(3):633–55. https://doi.org/10.1148/radiol.11091126. Epub 2011/08/19.CrossRefPubMed

11.

Abbas G, Danish A, Krasna MJ. Stereotactic body Radiotherapy and Ablative therapies for Lung Cancer. Surg Oncol Clin N Am. 2016;25(3):553–66. https://doi.org/10.1016/j.soc.2016.02.008. Epub 2016/06/05.CrossRefPubMed

12.

Moussa AM, Ziv E, Solomon SB, Camacho JC. Microwave ablation in primary lung malignancies. Semin Interv Radiol. 2019;36(4):326–33. https://doi.org/10.1055/s-0039-1700567. Epub 2019/11/05.CrossRef

13.

de Baere T, Tselikas L, Gravel G, Deschamps F. Lung ablation: best Practice/Results/Response Assessment/Role alongside other Ablative therapies. Clin Radiol. 2017;72(8):657–64. https://doi.org/10.1016/j.crad.2017.01.005. Epub 2017/02/22.CrossRefPubMed

14.

Yao W, Lu M, Fan W, Huang J, Gu Y, Gao F, et al. Comparison between microwave ablation and lobectomy for stage I non-small cell lung Cancer: a propensity score analysis. International journal of hyperthermia: the official journal of European Society for Hyperthermic Oncology. North Am Hyperth Group. 2018;34(8):1329–36. https://doi.org/10.1080/02656736.2018.1434901. Epub 2018/01/31.CrossRef

15.

Xue H, Qiu B, Wang H, Jiang P, Sukocheva O, Fan R et al. Stereotactic Ablative Brachytherapy: Recent Advances in Optimization of Radiobiological Cancer Therapy. Cancers. 2021; 13(14). Epub 2021/07/25. https://doi.org/10.3390/cancers13143493.

16.

Chen Y, Jiang Y, Ji Z, Jiang P, Xu F, Zhang Y, et al. Efficacy and safety of Ct-Guided (125)I seed implantation as a salvage treatment for locally recurrent Head and Neck Soft tissue sarcoma after surgery and External Beam Radiotherapy: a 12-Year study at a single Institution. Brachytherapy. 2020;19(1):81–9. https://doi.org/10.1016/j.brachy.2019.09.006. Epub 2019/10/28.CrossRefPubMed

17.

Qiu B, Aili A, Xue L, Jiang P, Wang J. Advances in Radiobiology of Stereotactic Ablative Radiotherapy. Front Oncol. 2020;10:1165. https://doi.org/10.3389/fonc.2020.01165. Epub 2020/08/28.CrossRefPubMedPubMedCentral

18.

Ji Z, Jiang Y, Tian S, Guo F, Peng R, Xu F, et al. The effectiveness and prognostic factors of Ct-Guided Radioactive I-125 seed implantation for the treatment of recurrent Head and Neck Cancer after External Beam Radiation Therapy. Int J Radiat Oncol Biol Phys. 2019;103(3):638–45. https://doi.org/10.1016/j.ijrobp.2018.10.034. Epub 2018/11/06.CrossRefPubMed

19.

Song Z, Ye J, Wang Y, Li Y, Wang W. Computed tomography-guided Iodine-125 brachytherapy for Unresectable Hepatocellular Carcinoma. J Cancer Res Ther. 2019;15(7):1553–60. https://doi.org/10.4103/jcrt.JCRT_629_19. Epub 2020/01/16.CrossRefPubMed

20.

Wang W, Li P, Wang Y, Liu B, Li Y. Percutaneous stenting and chemotherapy for unresectable pancreatic Cancer: comparison of irradiation stents vs conventional metal stents. Pancreatology. 2019;19(7):957–62. https://doi.org/10.1016/j.pan.2019.09.006. Epub 2019/09/26.CrossRefPubMed

21.

Ji Z, Huo B, Liu S, Liang Q, Xing C, Hu M et al. Clinical outcome of CT-Guided stereotactic ablative brachytherapy for Unresectable Early Non-small Cell Lung Cancer: a retrospective, Multicenter Study. Frontiers in oncology 2021; 11:706242. Epub 2021/10/05. https://doi.org/10.3389/fonc.2021.706242.

22.

Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. The Iaslc Lung Cancer Staging Project: proposals for revision of the Tnm Stage groupings in the Forthcoming (Eighth) Edition of the Tnm classification for Lung Cancer. J Thorac Oncol. 2016;11(1):39–51. https://doi.org/10.1016/j.jtho.2015.09.009. Epub 2016/01/15.CrossRefPubMed

23.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation Criteria in Solid tumours: revised Recist Guideline (Version 1.1). Eur J Cancer. 2009;45(2):228–47. https://doi.org/10.1016/j.ejca.2008.10.026. Epub 2008/12/23.CrossRefPubMed

24.

Ahmed M, Image-Guided Tumor A. Standardization of terminology and reporting Criteria–a 10-Year update: supplement to the Consensus Document. J Vascular Interventional Radiology: JVIR. 2014;25(11):1706–8. https://doi.org/10.1016/j.jvir.2014.09.005. Epub 2014/12/03.CrossRef

25.

Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom MR, Charboneau JW, et al. Image-guided tumor ablation: standardization of terminology and reporting Criteria–a 10-Year update. Radiology. 2014;273(1):241–60. https://doi.org/10.1148/radiol.14132958. Epub 2014/06/14.CrossRefPubMed

26.

Khalilzadeh O, Baerlocher MO, Shyn PB, Connolly BL, Devane AM, Morris CS, et al. Proposal of a new adverse event classification by the Society of Interventional Radiology Standards of Practice Committee. J Vascular Interventional Radiology: JVIR. 2017;28(10):1432–7..e3. Epub 2017/08/02.CrossRef

27.

National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer, Version 3. (2022). Available at: https://www.nccn.org/guidelines/guidelines-detail? Category = 1&id = 1450.

28.

Lencioni R, Crocetti L, Cioni R, Suh R, Glenn D, Regge D, et al. Response to Radiofrequency ablation of Pulmonary tumours: a prospective, intention-to-Treat, Multicentre Clinical Trial (the rapture study). Lancet Oncol. 2008;9(7):621–8. https://doi.org/10.1016/s1470-2045(08)70155-4. Epub 2008/06/21.CrossRefPubMed

29.

Okuma T, Matsuoka T, Yamamoto A, Oyama Y, Hamamoto S, Toyoshima M, et al. Determinants of local progression after computed tomography-guided percutaneous Radiofrequency ablation for unresectable lung tumors: 9-Year experience in a single Institution. Cardiovasc Interv Radiol. 2010;33(4):787–93. https://doi.org/10.1007/s00270-009-9770-9. Epub 2009/12/08.CrossRef

30.

Ahmed M, Brace CL, Lee FT Jr., Goldberg SN. Principles of and advances in percutaneous ablation. Radiology. 2011;258(2):351–69. https://doi.org/10.1148/radiol.10081634. Epub 2011/01/29.CrossRefPubMed

31.

Ambrogi MC, Fanucchi O, Cioni R, Dini P, De Liperi A, Cappelli C, et al. Long-term results of Radiofrequency ablation treatment of stage I non-small cell lung Cancer: a prospective intention-to-treat study. J Thorac Oncol. 2011;6(12):2044–51. https://doi.org/10.1097/JTO.0b013e31822d538d. Epub 2011/11/05.CrossRefPubMed

32.

Feng W, Liu W, Li C, Li Z, Li R, Liu F, et al. Percutaneous Microwave Coagulation Therapy for Lung Cancer. Zhonghua Zhong Liu Za Zhi. 2002;24(4):388–90. Epub 2002/11/01.PubMed

33.

Yang X, Ye X, Zheng A, Huang G, Ni X, Wang J, et al. Percutaneous microwave ablation of stage I medically inoperable Non-small Cell Lung Cancer: clinical evaluation of 47 cases. J Surg Oncol. 2014;110(6):758–63. https://doi.org/10.1002/jso.23701. Epub 2014/06/27.CrossRefPubMedPubMedCentral

34.

Yang X, Ye X, Lin Z, Jin Y, Zhang K, Dong Y, et al. Computed tomography-guided percutaneous microwave ablation for treatment of Peripheral Ground-Glass opacity-lung adenocarcinoma: a pilot study. J Cancer Res Ther. 2018;14(4):764–71. https://doi.org/10.4103/jcrt.JCRT_269_18. Epub 2018/07/05.CrossRefPubMed

35.

Watson RA, Tol I, Gunawardana S, Tsakok MT. Is microwave ablation an alternative to stereotactic ablative body radiotherapy in patients with inoperable early-stage primary lung Cancer? Interact Cardiovasc Thorac Surg. 2019;29(4):539–43. https://doi.org/10.1093/icvts/ivz123. Epub 2019/06/04.CrossRefPubMed

36.

Stewart A, Parashar B, Patel M, O’Farrell D, Biagioli M, Devlin P, et al. American Brachytherapy Society Consensus Guidelines for thoracic brachytherapy for Lung Cancer. Brachytherapy. 2016;15(1):1–11. https://doi.org/10.1016/j.brachy.2015.09.006. Epub 2015/11/13.CrossRefPubMed

37.

Chin J, Rumble RB, Kollmeier M, Heath E, Efstathiou J, Dorff T, et al. Brachytherapy for patients with prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update. J Clin Oncol. 2017;35(15):1737–43. https://doi.org/10.1200/jco.2016.72.0466. Epub 2017/03/28.CrossRefPubMed

38.

Chen C, Wang W, Yu Z, Tian S, Li Y, Wang Y. Combination of computed tomography-guided Iodine-125 brachytherapy and bronchial arterial chemoembolization for locally Advanced Stage Iii Non-small Cell Lung Cancer after failure of Concurrent Chemoradiotherapy. Lung Cancer. 2020;146:290–6. https://doi.org/10.1016/j.lungcan.2020.06.010. Epub 2020/07/03.CrossRefPubMed

39.

Qiu B, Jiang P, Ji Z, Huo X, Sun H, Wang J. Brachytherapy for Lung Cancer. Brachytherapy. 2021;20(2):454–66. https://doi.org/10.1016/j.brachy.2020.11.009. Epub 2020/12/29.CrossRefPubMed

40.

Uhlig J, Ludwig JM, Goldberg SB, Chiang A, Blasberg JD, Kim HS. Survival rates after thermal ablation Versus Stereotactic Radiation Therapy for Stage 1 Non-small Cell Lung Cancer: a National Cancer Database Study. Radiology. 2018;289(3):862–70. https://doi.org/10.1148/radiol.2018180979. Epub 2018/09/19.CrossRefPubMed

41.

Zhao H, Steinke K. Long-term outcome following microwave ablation of early-stage Non-small Cell Lung Cancer. J Med Imaging Radiat Oncol. 2020;64(6):787–93. https://doi.org/10.1111/1754-9485.13091. Epub 2020/07/29.CrossRefPubMed

42.

Brooks ED, Sun B, Feng L, Verma V, Zhao L, Gomez DR, et al. Association of Long-Term Outcomes and Survival with Multidisciplinary Salvage Treatment for Local and Regional Recurrence after Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer. JAMA Netw Open. 2018;1(4):e181390. https://doi.org/10.1001/jamanetworkopen.2018.1390. Epub 2019/01/16.CrossRefPubMedPubMedCentral

43.

Videtic GMM, Reddy CA, Woody NM, Stephans KL. Ten-year experience in implementing single-fraction lung SBRT for medically inoperable early-stage Lung Cancer. Int J Radiat Oncol Biol Phys. 2021;111(2):436–42. https://doi.org/10.1016/j.ijrobp.2021.05.116. Epub 2021/05/26.CrossRefPubMed

44.

Kashima M, Yamakado K, Takaki H, Kodama H, Yamada T, Uraki J, et al. Complications after 1000 lung radiofrequency ablation Sessions in 420 patients: a single Center’s experiences. AJR Am J Roentgenol. 2011;197(4):W576–80. https://doi.org/10.2214/ajr.11.6408. Epub 2011/09/24.CrossRefPubMed

Title: Stereotactic ablative brachytherapy versus percutaneous microwave ablation for early-stage non-small cell lung cancer: a multicenter retrospective study
Authors: Chuanwang Wu
Binglong Cao
Guanghui He
Yuliang Li
Wujie Wang
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: NSCLC
NSCLC
Brachytherapy
Pneumothorax
Pneumothorax
Pneumothorax
Published in: BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-024-12055-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

Association of the TRIM family protein with survival outcomes and clinicopathological features in colorectal cancer: a systematic review and meta-analysis

Clinical study of thoracoscopic assisted different surgical approaches for early thymoma: a meta-analysis

CLEC19A overexpression inhibits tumor cell proliferation/migration and promotes apoptosis concomitant suppression of PI3K/AKT/NF-κB signaling pathway in glioblastoma multiforme

HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: a real-world study

CNN-based multi-modal radiomics analysis of pseudo-CT utilization in MRI-only brain stereotactic radiotherapy: a feasibility study

Modulating DNA damage response in uveal melanoma through embryonic stem cell microenvironment

Keynote webinar | Spotlight on antibody–drug conjugates in cancer